Pharma/Biotech - Page 1 | TalkMarkets
All Posts > Content under Pharma/Biotech
1 to 16 of 1863 Posts
1 2 3 ... 117
IPO Preview: Zymeworks Inc.
Article By: Don Dion
Wednesday, April 26, 2017 11:42 AM EDT
Zymeworks reports that one of its risk factors is that its key product candidates are either in the pre-clinical stage or are in the early clinical stages of development.
In this article: ZYME
Read
Potential Biotech Breakout In Play
Article By: Ben Lockhart
Wednesday, April 26, 2017 9:15 AM EDT
Biotechs have avoided triggering a bearish chart pattern, and now look set to move higher in the near term.
In this article: IBB
Read
Akebia Therapeutics, Inc. Shares Shoot Up On Announcement Of Collaboration With Otsuka
Article By: TickerTV
Wednesday, April 26, 2017 8:45 AM EDT
AKBA opened trading yesterday at $9.38 which was up from the previous day’s trading close of $9.31. Shares closed trading yesterday at $9.37 and spiked up after market to $12.25, equivalent to a 31% increase from the closing price.
In this article: AKBA
Read
If You Own Just One Pharma Stock, Make It This
Article By: Michael A Robinson
Wednesday, April 26, 2017 6:42 AM EDT
For the biggest possible pharma profits, investors have to look ahead into the firm's "pipeline," its arsenal of yet-to-be-released drugs that's critical to keeping a drug company competitive in the long term.
In this article: SNY Also: REGN, GILD, FLXN
Read
Illumina Q1 Earnings Rise, 2017 Forecast In-Line
Article By: Lorimer Wilson
Tuesday, April 25, 2017 9:30 PM EDT
Illumina, Inc. (:ILMN) posted solid first quarter earnings results and offered a mixed outlook, with second quarter guidance well below the street, but full-year estimates in-line with expectations.
In this article: ILMN
Read
Biotech Digest – JAZZ Reports Positive Results, CTSO Inks New Contract, AMGN Forges Collaboration
Article By: KKD Healthcare Analytics
Tuesday, April 25, 2017 10:15 AM EDT
Capricor Therapeutics announced encouraging six-month results in a Phase 1/2 clinical trial. Jazz Pharmaceuticals reported results from its Phase 2/3 clinical trial. Amgen announced its new collaboration with Novartis.
In this article: NVS, EAPH, ACHN, JAZZ, AMGN, CANF, CAPR, CTSO
Read
Biogen Inc. Q1 Profit And Revenue Blow Away Expectations
Article By: Lorimer Wilson
Tuesday, April 25, 2017 9:10 AM EDT
Biogen Inc. posted market-beating first quarter earnings results, with revenues rising in most of its key drug segments.
In this article: BIIB
Read
Baby, We Were Born To Run
Article By: Michele Schneider
Monday, April 24, 2017 8:01 PM EDT
Both the Dow Jones and the S&P 500 gapped up over their 50 daily moving averages and back to unconfirmed bullish phases. They need a second close above the 50 DMA to confirm.
In this article: IBB, QQQ, DIA, IWM, SMH, SPY, XRT, IYT, KRE Also: GDX, GLD, IYR, SLV, TAN, TLT, USO, UUP
Read
Premarket Biotech Digest – BDX Finalizes Acquisition Deal, VNLPF Receives CRL, EYEG Files S-1
Article By: KKD Healthcare Analytics
Monday, April 24, 2017 10:03 AM EDT
Johnson & Johnson announced results from a Phase 2 clinical trial assessing the triple combination ofOlysio (simeprevir), C.R. Bard Inc. and Becton Dickinson finalize the deal for buying Bard.
In this article: BCR, JNJ, MRK, NVO, VNLPF, XOMA, EYEG, ARGNF, BDX
Read
Beware Of Fake Stock News In The Financial Markets
Article By: TipRanks
Sunday, April 23, 2017 4:56 PM EDT
The US Securities and Exchange Commission (SEC) is taking legal action against 27 individuals and several companies over hundreds of fake “impartial” blog posts that appeared on well-known financial websites.
In this article: ONCS, GALE, PBYI, ARTH, LBIO
Read
Beijing-Based BeiGene Study Of PD-1 Antibody For Patients With Relapsed Or Refractory Hodgkin Lymphoma Underway
Article By: Lorimer Wilson
Sunday, April 23, 2017 1:47 AM EDT
Beijing-based BeiGene has dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — in their Phase I PD-1 checkpoint trial of the drug BGB-A317 in a pivotal study which started less then four months ago.
In this article: BGNE Also: AZN, BMY, MRK, PFE, RHHBY, INCY, AGEN, TGTX
Read
French Presidential Election And Oil Price Fall Impact Global Markets
Article By: Equitymaster India
Sunday, April 23, 2017 1:13 AM EDT
Crude prices fell by 6.4% last week on growing concerns over increasing U.S production affecting OPEC's attempts to reduce the global oil shortage. US Markets ended 0.5% higher.
In this article: INDY Also: BNO, DBO, OIL
Read
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson
Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Read
E Conatus Pharmaceuticals Announces Two Poster Presentations At EASL Conference
Article By: Terry Chrisomalis
Saturday, April 22, 2017 4:34 PM EDT
Conatus Pharmaceuticals shows two posters at EASL conference that show a decrease in MELD might correlate with longer-term survival in transplant patients.
In this article: CNAT Also: NVS
Read
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today
Saturday, April 22, 2017 3:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Read
Valeant's $3,500 Sticker On Siliq Could Trigger A Pricing War With Lilly, Novartis
Article By: Lorimer Wilson
Saturday, April 22, 2017 11:20 AM EDT
Valeant Pharmaceuticals, one of the most obvious price-hiking offenders of the last couple of years, has just unveiled the sticker on its new psoriasis drug, Siliq—and it’s the lowest in the market for next-gen meds.
In this article: VRX Also: AZN, JNJ, NVS, AMGN, ESRX, ABBV, LLY
Read
1 to 16 of 1863 Posts
1 2 3 ... 117